Medicare GLP-1 starts July 1

FDA proposed excluding GLP-1s from the 503B bulk compounding list.

On Thursday April 30, the FDA tentatively found there is no clinical need for outsourcing facilities to compound semaglutide and tirzepatide in bulk.

Most telehealth brands fill compounded GLP-1s through 503A pharmacies, not 503B outsourcers. So the immediate operational hit is small.

The signal is what matters. The compounding pathway has narrowed every quarter for two years and the trend continues.

If your retention only works while compounded inventory is cheap, the model has a shelf life. Build retention now that survives a forced switch to branded molecules.

Medicare GLP-1 Bridge launches July 1.

CMS is opening a short-term demonstration that gives eligible Medicare Part D beneficiaries access to Foundayo, Wegovy, and Zepbound at a flat $50 monthly copay. It runs through December 2027.

For brands serving the older end of the market on cash-pay, this is the largest cohort migration event of the year. A patient currently paying you $250 a month for the same molecule has a built-in reason to defect in 60 days.

If you don't proactively address it in your flows, the news will reach them through a competitor's Facebook ad or a Reddit thread.

Digital health M&A is heating up around retention metrics.

In the past month: Spring Health bought Alma. Wisp bought TBD Health. Sword Health bought Kaia for $285M. The deal logic is consistent. Acquirers are paying for embedded patient bases and retention curves, not acquisition cost.

Even if you're not selling soon, this is the frame valuation gets graded on. Multi-month plan attach rate, churn after month 3, expansion revenue per patient. Those numbers are what an acquirer underwrites.

If you're building toward an exit in 18-24 months, retention is the line item that moves the multiple.

Pharmacy Compounding Advisory Committee charter renewed for July meeting.

The Federal Register confirmed renewal of the PCAC on April 30. The next public meeting is July 23-24, where peptides like BPC-157 and Sermorelin are on the agenda.

If the bans get walked back this summer, the next cross-sell category for telehealth opens up. If they don't, the longevity and recovery storyline tightens further.

Either way, build flexibility into your post-purchase flow now. A new category should drop into an existing onboarding sequence cleanly, not require a four-week build.

Medicare GLP-1 starts in 60 days. Most telehealth brands have not planned for it.

July 1, 2026. Eligible Medicare Part D beneficiaries can fill Foundayo, Wegovy, or Zepbound for a $50 flat copay through the new Bridge demonstration.

For a patient currently paying you $250 a month cash-pay for the same molecule, that is a $2,400 a year decision. The math will reach them whether you address it or not.

The brands that lose patients to this transition will be the ones that pretended it wasn't happening.

1. The defection cohort is already in your CRM. You can name them today.

Pull your active patient list. Filter by age 60+ and active on monthly cash-pay GLP-1.

That is your at-risk cohort for July. Most brands have somewhere between a few hundred and a few thousand patients in this segment depending on category and scale.

Treat it as a named segment with its own communication track. Not a tag you use once. A persistent segment your team checks weekly between now and August.

2. Your value proposition has 60 days to stop being "we get you the medication."

A Medicare patient on the Bridge gets a covered molecule and a prescription fill. They do not get clinical optimization, dose titration support, lab review, side effect coaching, or a provider relationship that follows them through plateau and maintenance.

That is the gap your retention has to occupy. Not "we are cheaper" (you are not anymore). Not "we are faster" (Medicare timelines vary but the gap is closing).

The pitch becomes "we are the team that gets you results, not just the prescription." That has to show up in the actual flows. A weekly check-in email. A side effect troubleshooting page. A named provider reply path. Lab review at month three.

3. Invest in the relationship now, not in July.

The next 60 days are the window where retention is built or eroded for this cohort.

Route higher-touch content to the at-risk segment specifically. A personal note from the named provider. A lab review prompt. A check-in on side effects or plateau reframing.

The patient experience in May and June should be visibly richer than it was in March. So if anything tests the relationship in July, the patient already has a current, lived reason to stay.

4. Watch the cohort. Act only if dropoff shows up.

Track the segment's open rates, cancellation rate, and cancellation reasons through July and August.

If you see real defection signals (a spike in cancellations, a dip in engagement, "found cheaper elsewhere" or "switching to insurance" appearing in cancel reasons), that's when you act. A targeted save offer, a plan adjustment conversation, a personal outreach from the provider.

If the data doesn't move, the relationship investment is doing its job. Keep the cadence and let the metrics tell you whether to escalate.

Takeaway: A flat $50 copay landing on July 1 is the kind of market shift that exposes whether your retention is real or vibes. The work for May and June is to make the patient experience rich enough that the relationship holds. The cohort tells you whether it did.

The compounding moat just shrank again.

The FDA's 503B exclusion is mostly symbolic for now. Most telehealth GLP-1 fills run through 503A pharmacies that aren't directly affected.

But the regulatory direction is unambiguous. Compounding access narrows every quarter. If your unit economics depend on compounded inventory staying cheap, your business has a clock on it.

The brands that survive are the ones whose retention works on branded molecules at branded prices.

M&A is grading you on retention, not on revenue.

The recent wave (Spring Health, Wisp, Sword) priced the deals around embedded patient bases and the rate at which those patients renew, expand, and refer.

Top-line revenue gets you in the room. Multi-month attach rate, post-month-3 churn, and expansion revenue per patient set the multiple.

If you're building toward an exit window in the next two years, retention is the line item that moves the valuation.

The patient who knows their provider's name doesn't shop on price.

Amazon at $149. Ro at $74. Medicare Bridge at $50. Walmart at $49 visit fees.

The price floor keeps moving. The brands holding patients aren't the ones racing to match it. They're the ones whose patients can name a provider, recall a specific lab review, and remember the email that helped them push through week six nausea.

Trust beats price. But it has to be built into the flow, not assumed.

Pull your active GLP-1 patient list. Filter for anyone aged 60 and up on monthly cash-pay.

That's the cohort to watch through the summer. Tag it persistently in your ESP so you can monitor it as a stable segment, not a one-time filter.

Over the next 60 days, route higher-touch content to that segment specifically. A personal note from their named provider. A clinical lab review prompt. A check-in on side effects or plateau reframing. Make the patient experience demonstrably richer than what a prescription-fill service offers.

Then watch the cohort weekly. Track open rates, cancellation rate, and cancel reasons through July. If you see dropoff, that's when you act, with a targeted save (plan adjustment, provider outreach, downsell).

The frame: identify the cohort early, invest in the relationship now, and let the metrics tell you whether anything more is needed.

If retention is your biggest revenue leak, that’s what we fix. growthtrigger.xyz

Reply to this with your biggest retention challenge. I read and respond to every single one.